MGTX (MeiraGTx Holdings plc) stock: $13.25, $1.27B market cap, $143.2M cash, $1.13B EV, $1.49B fully diluted market cap. Next expected readout: Mar-27. Lead program: AAV2-hAQP1 Concentration 1 (Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of th), Phase 2. Data from Fully Diluted's biotech stocks database.
Enterprise value
$1,129.4M
Balance sheet
| Cash | $143.2M |
|---|
| Debt | $0.0M |
|---|
| Net cash | $143.2M |
|---|
| Enterprise value | $1,129.4M |
|---|
| Basic shares | 94.2M shares |
|---|
| Fully diluted shares | 112.1M shares |
|---|
| Fully diluted market cap | $1,485.6M |
|---|
| Cash per share | $1.52 |
|---|
Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.
Price history
Loading MGTX daily closes…
Loading price history…
Upcoming catalysts
| Expected | Drug | Phase | Indication | Mgmt guide |
|---|
| Jul 13 - Aug 24 | AAV2-hAQP1 Concentration 1 | Phase 2 | Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of th | — |
| Nov 12 - Dec 24 | AAV-GAD | Phase 1/2 | Parkinson's Disease | — |
| Mar 14 - Apr 25 | AAV2-hAQP1 | Phase 2 | Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of th | — |
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Full readout calendar →
Pipeline assets
AAV-GAD
Phase 1 · Active Modality: Gene therapy (one-time bilateral subthalamic-nucleus infusion)
Target GAD (glutamic acid decarboxylase)
Partnerships Hologen (Mar 2025 strategic collaboration via Reogen joint venture): $200M upfront + up to $230M to fund AAV-GAD development to commercialization; uses Hologen AI on trial data; company manufactures/supplies drug product
Indications- Parkinson's disease (Phase 1)
Status note Phase 1 bridging study MGT-GAD-025 (14 pts, commercial platform process) completed; data announced Oct 2024. FDA RMAT designation granted May 2025 for Parkinson's disease not adequately controlled with anti-Parkinsonian medications. Hologen collaboration funded to advance to commercialization.
AAV-BDNF
Stage not disclosed · Active Modality: Gene therapy (local CNS delivery)
Target BDNF
Partnerships Hologen / Reogen joint venture (Clinical Programs); company manufactures/supplies
Indications- Genetic obesity disorders (Stage not disclosed)
Status note Investigational gene therapy for genetic obesity disorders, one of the CNS Clinical Programs under the Hologen/Reogen collaboration. 10-Q does not state trial phase.
AAV-AIPL1
Stage not disclosed · Active Modality: Gene therapy (subretinal rAAV8.hRKp.AIPL1)
Target AIPL1
Partnerships Eli Lilly (Nov 2025 strategic collaboration and license): exclusive worldwide rights to research, develop and commercialize AAV-AIPL1, plus two other preclinical IRD candidates, intravitreal capsids/promoters licenses, ophthalmology right of first designation
Indications- Leber congenital amaurosis 4 (AIPL1 gene mutations) (Stage not disclosed)
Status note AAV-AIPL1 manufactured/released for compassionate use (MHRA specials license, UK; 11 children). First-in-human interventional study published in The Lancet (Feb 2025). No phase stated in the 10-Q.
AAV-CNGB3
Phase 1/2 · Active Modality: Gene therapy
Target CNGB3
Indications- Achromatopsia (CNGB3 mutations) (Phase 1/2)
Status note One of three Phase 1/2 IRD programs the company may develop itself or with a strategic partner.
AAV-CNGA3
Phase 1/2 · Active Modality: Gene therapy
Target CNGA3
Indications- Achromatopsia (CNGA3 mutations) (Phase 1/2)
Status note One of three Phase 1/2 IRD programs the company may develop itself or with a strategic partner.
AAV-RPE65
Phase 1/2 · Active Modality: Gene therapy
Target RPE65
Indications- Retinal dystrophy (RPE65 deficiency) (Phase 1/2)
Status note One of three Phase 1/2 IRD programs the company may develop itself or with a strategic partner.
AAV-BBS10
Stage not disclosed · Active Modality: Gene therapy
Target BBS10
Indications- Bardet-Biedl syndrome (BBS10 mutations) (Stage not disclosed)
Status note Manufactured and released for compassionate use (MHRA specials license, UK). No phase stated in the 10-Q.
Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.